Azalea Therapeutics, a Jennifer Doudna‑linked spinout, announced an $82 million raise to develop in‑vivo CAR‑T approaches intended to convert patients’ immune cells directly inside the body. The company positions its platform as a single‑infusion alternative to ex‑vivo CAR‑T manufacturing, aiming to lower cost and broaden access. The financing illustrates sustained investor interest in gene‑editing and in‑vivo cell engineering as companies race to simplify cell therapy production and expand indications beyond blood cancers.